Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Juvenile Absence Epilepsy: later-stage trial registry
1 of 2 indexed Juvenile Absence Epilepsy trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Juvenile Absence Epilepsy: 2 US clinical trials tracked, 1 recruiting.
Juvenile Absence Epilepsy is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is UCB Biopharma SRL, running 2 of these trials.
Enrollment posture brief
Registry condition juvenile-absence-epilepsy
OPEN 1 | RECR 50% | LATE 2 | EARLY 0 | RANK #7188 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Juvenile Absence Epilepsy lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Juvenile Absence Epilepsy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Juvenile Absence Epilepsy is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
UCB Biopharma SRL
NCT06315322
A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
UCB Biopharma SRL
NCT04666610
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Juvenile Absence Epilepsy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Juvenile Absence Epilepsy trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Juvenile Absence Epilepsy page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Juvenile Absence Epilepsy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- UCB Biopharma SRL sponsors the most Juvenile Absence Epilepsy trials on record, review their full trial history before evaluating a specific study. See UCB Biopharma SRL's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Juvenile Absence Epilepsy condition card totals 2 registered trials; most-linked intervention Brivaracetam oral solution; top US site state New Jersey. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.